NCT00094666
Terminated
Phase 3
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Elderly Patients With Primary Insomnia
ConditionsPrimary Insomnia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Primary Insomnia
- Sponsor
- H. Lundbeck A/S
- Enrollment
- 465
- Primary Endpoint
- Amount of time spent awake and time to fall asleep at night after two days
- Status
- Terminated
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Elderly patients with a diagnosis of primary insomnia and in good physical and mental health
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Amount of time spent awake and time to fall asleep at night after two days
Secondary Outcomes
- Amount of time spent awake and time to fall asleep at night after 30 days
- Amount of deep sleep after two days
Similar Trials
Completed
Phase 3
Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)Primary InsomniaNCT00094627H. Lundbeck A/S465
Withdrawn
Phase 3
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)InsomniaNCT00102154H. Lundbeck A/S
Completed
Phase 2
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)Alzheimer's DiseaseNCT00420420Merck Sharp & Dohme LLC144
Completed
Phase 2
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic PainPainDiabetic NeuropathiesNCT00375960Vernalis (R&D) Ltd50
Completed
Phase 2
Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00600171GlaxoSmithKline614